Immunological backbone of uveal melanoma: Is there a rationale for immunotherapy?

Alessandra Cassano, Guido Rindi, Emilio Bria, Maria Antonietta Blasi, Giampaolo Tortora, Ernesto Rossi, Giovanni Schinzari, Brigida Anna Maiorano, Monica Maria Pagliara, Vincenzo Fiorentino, Gianluigi Petrone, Ilaria Grazia Zizzari, Marianna Nuti

Risultato della ricerca: Contributo in rivistaArticolo in rivista

10 Citazioni (Scopus)

Abstract

No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.
Lingua originaleEnglish
pagine (da-a)1055-1066
Numero di pagine12
RivistaCancers
Volume11
DOI
Stato di pubblicazionePubblicato - 2019

Keywords

  • Checkpoint inhibitors
  • IDO
  • Immunotherapy
  • Ipilimumab
  • Nivolumab
  • PD-L1
  • Pembrolizumab
  • Uveal melanoma

Fingerprint Entra nei temi di ricerca di 'Immunological backbone of uveal melanoma: Is there a rationale for immunotherapy?'. Insieme formano una fingerprint unica.

Cita questo